Medtronic is releasing new research that demonstrates the progress that has been made in the development and commercialisation of artificial pancreas technology, including future innovations and new systems coming onto the market.

The first clinical study results on how their Hybrid Closed System affects outpatients were revealed at the Advanced Technologies and Treatments for Diabetes 8th Annual Meeting, along with new data on the performance of the MiniMed 670G and Elite 3 system in type 1 diabetes, that was trialled at an overnight diabetes camp.

Diabetes NSW Credentialled Diabetes Educator, Sue Leahy said the research findings hold potential to encourage more freedom among kids and teens.

“We host camps for kids and teens with type 1 diabetes and if these products are successful they could significantly enhance confidence and independence amongst this age group when it comes to looking after their diabetes,†Sue said.

Meanwhile the MiniMed 640G is becoming renowned for being the most sophisticated insulin pump and continuous monitoring system in the world.

“The 640G was released in Australia earlier this year, and is a big step towards a fully automated artificial pancreas. The technology additionally provides advanced protection against hypoglycaemia (low blood glucose) which is extremely exciting because that will help prevent some of the serious complications associated with the disease,†Sue said.